Advocacy intelligence hub — real-time data for patient organizations
IMATINIB MESYLATE: New indication approved
Peking Union Medical College Hospital — PHASE2
National Cancer Institute (NCI) — PHASE2
St. Petersburg State Pavlov Medical University — PHASE2
IMATINIB MESYLATE: New indication approved
Karolinska University Hospital — PHASE2
M.D. Anderson Cancer Center — PHASE2
IMATINIB MESYLATE: FDA approved
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs1
Imatinib Mesylate
Apotex Corp
Imatinib Mesylate
(IMATINIB MESYLATE)Orphan drugstandardApotex Corp
12.1 Mechanism of Action Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the BCR-ABL tyrosine kinase, the constitutive abnormal...
Imkeldi
(IMATINIB ORAL)Orphan drugstandardShorla Oncology Inc.,
12.1 Mechanism of Action Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the BCR-ABL tyrosine kinase, the constitutive abnormal...
Browse all Myelodysplastic/myeloproliferative disease news →
Hagop Kantarjian, MD, MD
M.D. Anderson Cancer Center
📍 HOUSTON, TX
Minocher Battiwalla, MD, MD
National Institutes of Health- NHLBI
📍 NASHVILLE, TN
Farhad Ravandi-Kashani, M.D
SWOG Cancer Research Network
📍 HOUSTON, TX
Corey Cutler, MD, MPH, F.N.P
Dana-Farber Cancer Institute
📍 PARK CITY, UT
Farhad Ravandi-Kashani, MD, M.D
M.D. Anderson Cancer Center
📍 HOUSTON, TX
Abhay Singh, MD, MPH
Case Comprehensive Cancer Center, Cleveland Clinic Taussig Cancer Institute
📍 Cleveland, Ohio
View all Myelodysplastic/myeloproliferative disease specialists →